Arca
Skip to content
Tools
Tools

OPRK1: Kappa-type opioid receptor

G protein-coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins.

  • Drugs that act on it: 14
  • Approved: 9
  • In phases 1 to 3: 5
  • Sponsors: 13

Who is on it, and how far along

Every drug ChEMBL records acting on OPRK1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 13
  • Protein or peptide 1

Approved9

  • Buprenorphine
  • Nalfurafine
  • Dezocine
  • Samidorphan
  • Nalmefene
  • Difelikefalin
  • Butorphanol
  • Anileridine
  • Levallorphan

Phase 33

  • Asimadoline
  • Aticaprant
  • Navacaprant

Phase 22

  • Axomadol
  • ORP-101

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
    BuprenorphineBoxed warningApprovedIndiviorSmall moleculeAgonistKappa opioid receptor agonist130
    NalfurafineApprovedImmunisSmall moleculeAgonistKappa opioid receptor agonist5
    DezocineApprovedAstraZeneca PharmaceuticalsSmall moleculeAntagonistKappa opioid receptor antagonist4
    SamidorphanApprovedAlkermesSmall moleculePartial agonistKappa opioid receptor partial agonist4
    NalmefeneApprovedHikma PharmaceuticalsSmall moleculePartial agonistKappa opioid receptor partial agonist3
    DifelikefalinApprovedCSLProtein or peptideAgonistKappa opioid receptor agonist2
    ButorphanolBoxed warningApprovedBristol-Myers SquibbSmall moleculePartial agonistKappa opioid receptor partial agonist1
    AnileridineApproved—Small moleculeAgonistKappa opioid receptor agonist0
    LevallorphanApprovedRocheSmall moleculePartial agonistKappa opioid receptor partial agonist0
    AsimadolinePhase 3Tioga PharmaceuticalsSmall moleculeAgonistKappa opioid receptor agonist1
    AticaprantPhase 3Johnson & JohnsonSmall moleculeAntagonistKappa opioid receptor antagonist1
    NavacaprantPhase 3Neumora Therapeutics, Inc.Small moleculeAntagonistKappa opioid receptor antagonist0
    AxomadolPhase 2Grünenthal GmbHSmall moleculeAgonistKappa opioid receptor agonist0
    ORP-101Phase 2OrphoMedSmall moleculeAntagonistKappa opioid receptor antagonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 29 in all, from ClinicalTrials.gov.
    A Study of a New Induction and Dosing Schedule for Sublocade in Opioid Use DisorderBuprenorphinePhase 2Not yet recruitingThe Smart ClinicNov 20, 2026
    Low-Dose IV Buprenorphine vs Hydromorphone for Acute Pain in the EDBuprenorphinePhase 2Not yet recruitingStanford UniversityNov 17, 2026
    Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated DyskinesiaNalfurafinePhase 1Not yet recruitingImmunis, Inc.Oct 30, 2026
    Cannabidiol in Opioid Use Disorder and Chronic Pain With BuprenorphineBuprenorphineEarly phase 1RecruitingYale UniversityOct 21, 2026
    Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction ClinicsBuprenorphineNot applicableNot yet recruitingVanderbilt University Medical CenterSep 24, 2026
    Buprenorphine for the Management of Pain in Children With Sickle Cell DiseaseBuprenorphinePhase 1Not yet recruitingNatasha ArcherSep 2, 2026
    BUprenorphine Versus Morphine for Postcesarean Analgesia (BUMP)BuprenorphinePhase 4RecruitingIcahn School of Medicine at Mount SinaiAug 25, 2026
    TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following HospitalizationBuprenorphineNot applicableEnrolling by invitationT. John Winhusen, PhDAug 21, 2026
    Personalized Addiction Treatment enHancementBuprenorphineNot applicableRecruitingRhode Island HospitalAug 21, 2026
    Perioperative Dezocine Administration and Postoperative Delirium in Elderly Cardiac Surgery PatientsDezocineNot applicableNot yet recruitingChinese Academy of Medical Sciences, Fuwai HospitalAug 17, 2026
    Efficacy of Nalfurafine for Chronic Kidney Disease-Associated Pruritus in Twice-Weekly Hemodialysis Patients: A Randomized Controlled TrialNalfurafinePhase 4Not yet recruitingUniversitas IndonesiaAug 17, 2026
    A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic CholecystectomyDezocinePhase 2Not yet recruitingAffiliated Hospital of Guangdong Medical UniversityAug 3, 2026
    Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance HemodialysisNalfurafineNot applicableNot yet recruitingChinese PLA General HospitalJun 16, 2026
    A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaAticaprantPhase 1RecruitingJanssen Research & Development, LLCMay 29, 2026
    Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRPDezocineNot applicableRecruitingZhejiang UniversityMay 27, 2026
    Difelikefalin for Itching in Hemodialysis Patients With Chronic Kidney DiseaseDifelikefalinNot applicableNot yet recruitingChittagong Medical CollegeApr 13, 2026
    Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial.DezocineNot applicableRecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFeb 10, 2026
    Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aPNalfurafinePhase 4RecruitingZhujiang HospitalFeb 2, 2026
    Nalmefene Implant in Healthy SubjectsNalmefenePhase 1RecruitingReacX Pharmaceuticals, Inc.Jan 8, 2026
    Butorphanol for Pain Relief After Cesarean Section: A Retrospective StudyButorphanol—Not yet recruitingSichuan Provincial People's HospitalSep 16, 2025
    Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal DialysisNalfurafineNot applicableRecruitingGuangdong Provincial People's HospitalAug 1, 2025
    Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).AsimadolinePhase 2RecruitingTioga PharmaceuticalsJun 29, 2025
    Exercise and Olanzapine-samidorphanSamidorphanPhase 4RecruitingNew York State Psychiatric InstituteDec 18, 2024
    TH104 for the Treatment of Pruritus in Primary Biliary CholangitisNalmefenePhase 2Not yet recruitingTharimmune IncDec 13, 2024
    Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe PruritusDifelikefalinPhase 2RecruitingVifor Fresenius Medical Care Renal PharmaSep 19, 2024
    NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural AddictionsNalmefenePhase 3RecruitingNantes University HospitalSep 14, 2022
    Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderSamidorphanPhase 3RecruitingAlkermes, Inc.Mar 31, 2022
    Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsSamidorphanPhase 3Enrolling by invitationAlkermes, Inc.Aug 3, 2021
    National Pregnancy Registry for Psychiatric MedicationsSamidorphan—RecruitingMassachusetts General HospitalNov 23, 2010

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Alcohol dependence0.62
    • Pain0.61
    • Opiate dependence0.61
    • Drug dependence0.60
    • Obesity disorder0.58
    • Overweight0.52

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL237, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41145, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.